{"component":{"type":17,"accent_color":10660273,"components":[{"type":10,"content":"-# WikiRNG · Roll of 10/21/2026 · by [Romaing](https://wikirng.com/u/Romaing)"},{"type":10,"content":"## [Duligotuzumab](https://wikirng.com/roll/L3U11MXcnQ)\n*Monoclonal antibody*"},{"type":10,"content":">>> Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3. It is in development by Roche."},{"type":14,"divider":true,"spacing":1},{"type":10,"content":"### ⬜ Basic · 23,590 SP\n-# Bottom 25%"},{"type":14,"divider":true,"spacing":1},{"type":10,"content":"🟩 🌐 **.int** · Notable · +9,063 SP\n-# Links to an international organization (.int).\n🟩 🦓 **Zebra** · Notable · +6,936 SP\n-# The title's letters alternate vowel and consonant (7+ letters).\n🟩 🛞 **Hub** · Notable · +3,119 SP\n-# 500+ articles link here.\n⬜ 1️⃣ **One Word** · Basic · +812 SP\n-# Title is one word.\n⬜ 🔬 **Peer Reviewed** · Basic · +700 SP\n-# Cites a journal article.\n⬜ 🚫 **Lipogram** · Basic · +626 SP\n-# No letter E in a title of 10+ letters.\n-# +10 more badges"},{"type":14,"divider":true,"spacing":1},{"type":1,"components":[{"type":2,"style":5,"label":"View roll","url":"https://wikirng.com/roll/L3U11MXcnQ"},{"type":2,"style":5,"label":"Read on Wikipedia","url":"https://en.wikipedia.org/wiki/Duligotuzumab"}]},{"type":10,"content":"-# Article text from Wikipedia, CC BY-SA 4.0"}]}}